Team:Wageningen UR/Secondary metabolites
From 2013.igem.org
Karrenbelt (Talk | contribs) |
Karrenbelt (Talk | contribs) |
||
Line 62: | Line 62: | ||
<div class="tournav"> | <div class="tournav"> | ||
<ul> | <ul> | ||
- | <li class="first fill">Why <i>Aspergillus nigem</i>?</li> | + | <li class="first fill"><a href="https://2013.igem.org/Team:Wageningen_UR/Why_Aspergillus_nigem">Why <i>Aspergillus nigem</i>?</a></li> |
<li class="smbg current">Secondary metabolites</li> | <li class="smbg current">Secondary metabolites</li> | ||
<li class="bgbg"><a href="https://2013.igem.org/Team:Wageningen_UR/Lovastatin">Lovastatin</a></li> | <li class="bgbg"><a href="https://2013.igem.org/Team:Wageningen_UR/Lovastatin">Lovastatin</a></li> | ||
Line 77: | Line 77: | ||
<div class="tournav"> | <div class="tournav"> | ||
<ul> | <ul> | ||
- | <li class="first fill">Why <i>Aspergillus nigem</i>?</li> | + | <li class="first fill"><a href="https://2013.igem.org/Team:Wageningen_UR/Why_Aspergillus_nigem">Why <i>Aspergillus nigem</i>?</a></li> |
<li class="smbgsm current">Secondary metabolites</li> | <li class="smbgsm current">Secondary metabolites</li> | ||
<li><a href="https://2013.igem.org/Team:Wageningen_UR/Lovastatin">Lovastatin</a></li> | <li><a href="https://2013.igem.org/Team:Wageningen_UR/Lovastatin">Lovastatin</a></li> | ||
Line 92: | Line 92: | ||
<div class="tournav"> | <div class="tournav"> | ||
<ul> | <ul> | ||
- | <li class="first fill">Why <i>Aspergillus nigem</i>?</li> | + | <li class="first fill"><a href="https://2013.igem.org/Team:Wageningen_UR/Why_Aspergillus_nigem">Why <i>Aspergillus nigem</i>?</a></li> |
<li class="smbgsm current">Secondary metabolites</li> | <li class="smbgsm current">Secondary metabolites</li> | ||
<li><a href="https://2013.igem.org/Team:Wageningen_UR/Lovastatin">Lovastatin</a></li> | <li><a href="https://2013.igem.org/Team:Wageningen_UR/Lovastatin">Lovastatin</a></li> | ||
Line 107: | Line 107: | ||
<div class="tournav"> | <div class="tournav"> | ||
<ul> | <ul> | ||
- | <li class="first fill">Why <i>Aspergillus nigem</i>?</li> | + | <li class="first fill"><a href="https://2013.igem.org/Team:Wageningen_UR/Why_Aspergillus_nigem">Why <i>Aspergillus nigem</i>?</a></li> |
<li class="smbgsm current">Secondary metabolites</li> | <li class="smbgsm current">Secondary metabolites</li> | ||
<li><a href="https://2013.igem.org/Team:Wageningen_UR/Lovastatin">Lovastatin</a></li> | <li><a href="https://2013.igem.org/Team:Wageningen_UR/Lovastatin">Lovastatin</a></li> |
Revision as of 13:26, 4 October 2013
- Why Aspergillus nigem?
- Secondary metabolites
- Toolbox
- Host engineering
- Summary
- Safety introduction
- General safety
- Fungi-related safety
- Biosafety Regulation
- Safety Improvement Suggestions
- Safety of the Application
Secondary metabolites
An infinity field
- Why Aspergillus nigem?
- Secondary metabolites
- Lovastatin
- Modeling
- Biosensors
- Infrastructure
- Chromoproteins
- Host engineering
- Summary
- Why Aspergillus nigem?
- Secondary metabolites
- Lovastatin
- Modeling
- Biosensors
- Infrastructure
- Chromoproteins
- Host engineering
- Summary
- Why Aspergillus nigem?
- Secondary metabolites
- Lovastatin
- Modeling
- Biosensors
- Infrastructure
- Chromoproteins
- Host engineering
- Summary
- Why Aspergillus nigem?
- Secondary metabolites
- Lovastatin
- Modeling
- Biosensors
- Infrastructure
- Chromoproteins
- Host engineering
- Summary
- Why Aspergillus nigem?
- Secondary metabolites
- Lovastatin
- Modeling
- Biosensors
- Infrastructure
- Chromoproteins
- Host engineering
- Summary
Natural products
Secondary metabolites are the products of metabolism not essential for normal growth, development or reproduction of an organism. They meet the secondary requirements of the producing organisms, empower them to survive interspecies competition, provide defensive mechanisms and facilitate reproductive processes. Well known sources of secondary metabolites are plants, bacteria, fungi and marine organisms such as sponges, tunicates, corals and snails.
Well-known medical uses
Secondary metabolites are well-known as antimicrobials. Currently, many secondary metabolites have been proven to be effective as antibacterial or antifungal agents, anticancer drugs, cholesterol-lowering agents, immunosuppressants, antiparasitic agents, herbicides, diagnostics, and even tools for other researches.
Cholesterol-lowering agents
Compactin was first reported as a cholesterol-lowering drug by Endo in 1985. The fungal fermentation products lovastatin produced by Aspergillus terreus and Monascus ruber was found to be highly effective in reducing serum cholesterol in humans, especially cholesterol LDL levels. Lovastatin is a potent inhibitor of 3-hydroxy-3-methylglutaryl-CoA reductase and blocks formation of all products of the mammalian polyisoprenoid pathway, thus reducing the risk of cardiovascular disease.
Extensive applications
Exploiting the therapeutic potential of fungi
In addition to their known roles in combating disease, secondary metabolites reveal surprising additional activities, which may be possible solutions to other treatment lacking diseases. Many antibiotics, bacterial pigments and plant terpenoids, are also found to have anti-HIV, antitumor, anti-ageing, immunosuppressant, antiprotozoal and antihelminth activities, thus exhibiting multifarious applications in the sphere of medicine.
Unraveling the novel applications of known secondary metabolites and exploiting a myriad of sources as microbes, plants and higher animals for screening new secondary metabolites are paving the way to treat “untreatable diseases”, and help reduce mortality rates. The study of those useful activities of secondary metabolites against life-threatening diseases may catalyze further efforts to apply them against other forms of human disease.